{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T11:23:38Z","timestamp":1778066618177,"version":"3.51.4"},"reference-count":48,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002713","name":"Deanship of Scientific Research at Imam Mohammad Ibn Saud Islamic University (IMSIU)","doi-asserted-by":"publisher","award":["IMSIU-DDRSP2501"],"award-info":[{"award-number":["IMSIU-DDRSP2501"]}],"id":[{"id":"10.13039\/501100002713","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: In the present systematic review and meta-analysis, we aimed to discover the overall efficacy of azithromycin in children with cystic fibrosis (CF) and with or without Pseudomonas aeruginosa infection, specifically regarding its effect on respiratory parameters such as forced expiratory volume in 1 s (FEV1) and forced vital capacity (FVC) in addition to its effect on exacerbations and the need to use additional antibiotics. Materials and Method: We conducted this systematic review and meta-analysis by searching for all eligible articles on PubMed, Web of Science, and Scopus published between inception and September 2024. We used the following search strategy for our searching process: \u201cCystic fibrosis\u201d AND \u201cAzithromycin\u201d and \u201cChildren\u201d OR \u201cPediatric\u201d OR \u201cInfant\u201d. We conducted the meta-analysis by pooling the mean difference (MD) and comparing the continuous variables and odds ratio (OR) for dichotomous variables at 95% confidence intervals (CI), at a p-value of 0.05. Results: Azithromycin was observed to be associated with increased FEV1 compared with the control, showing an MD of 1.91 (95% CI: 1.09, 2.74, p &lt; 0.00001) and non-significant heterogeneity. However, no significant difference was observed between azithromycin and control groups regarding FVC with MD = 0.62 (95% CI: \u22120.01, 1.25, p = 0.06). Compared with the control group, azithromycin was significantly associated with lower risk and a lower number of exacerbations, with OR = 0.48 (95% CI: 0.34, 0.67, p &lt; 0.0001) and MD = \u22120.82 (95% CI: \u22121.32, \u22120.33, p = 0.001), respectively, with non-significant heterogeneity. Regarding the need for new antibiotic usage, azithromycin showed a significantly lower need, with OR = 0.35 (95% CI: 0.13, 0.94, p = 0.04), I2 = 75%, p = 0.02. No significant difference was observed between both groups regarding hospitalization rate, with OR = 0.88 (95% CI: 0.55, 1.4, p = 0.59). Conclusions: This systematic review and meta-analysis showed the efficacy of azithromycin in pediatric patients with CF, as it improved lung function by increasing FEV1, reduced exacerbations of CF, which is the most common symptom of CF that leads to mortality, and reduced the number of antibiotics that needed to be administered to patients with CF, which reduces the risk of antibiotic resistance. Therefore, the long-term use of azithromycin is recommended for pediatric patients with CF as part of their treatment regimen.<\/jats:p>","DOI":"10.3390\/medicina61040653","type":"journal-article","created":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T07:47:44Z","timestamp":1743580064000},"page":"653","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy of Long-Term Use of Azithromycin in the Management of Cystic Fibrosis in Pediatric Patients with or Without Pseudomonas aeruginosa: A Systematic Review and Meta-Analysis Article"],"prefix":"10.3390","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2972-8276","authenticated-orcid":false,"given":"Hassan","family":"Al-shehri","sequence":"first","affiliation":[{"name":"Department of Pediatrics, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Albassam","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, College of Medicine, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh 13317, Saudi Arabia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e20162642","DOI":"10.1542\/peds.2016-2642","article-title":"Characterization of Inpatient Cystic Fibrosis Pulmonary Exacerbations","volume":"139","author":"Cogen","year":"2017","journal-title":"Pediatrics"},{"key":"ref_2","first-page":"554","article-title":"Clinical and laboratory profile of children with Cystic Fibrosis: Experience of a tertiary care center in Pakistan","volume":"33","author":"Aziz","year":"2017","journal-title":"Pak. J. Med. Sci."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and Epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.biocel.2014.02.004","article-title":"CFTR structure and cystic fibrosis","volume":"52","author":"Cant","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.biocel.2014.02.009","article-title":"Effects of airway surface liquid pH on host defense in cystic fibrosis","volume":"52","author":"Berkebile","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMra1300109","article-title":"Origins of cystic fibrosis lung disease","volume":"372","author":"Stoltz","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jcf.2015.03.003","article-title":"Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy","volume":"14","author":"Cantin","year":"2015","journal-title":"J. Cyst. Fibros."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1002\/ppul.23242","article-title":"Inflammation and its genesis in cystic fibrosis","volume":"50","author":"Nichols","year":"2015","journal-title":"Pediatr. Pulmonol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1136\/thx.2006.060889","article-title":"Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis","volume":"62","author":"Goss","year":"2007","journal-title":"Thorax"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1183\/09031936.03.00057003","article-title":"New concepts of the pathogenesis of cystic fibrosis lung disease","volume":"23","author":"Boucher","year":"2004","journal-title":"Eur. Respir. J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1164\/ajrccm.152.6.8520783","article-title":"Inflammatory cytokines in cystic fibrosis lungs","volume":"152","author":"Bonfield","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1001\/jama.290.13.1749","article-title":"Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"290","author":"Saiman","year":"2003","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.2010.563","article-title":"Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: A randomized controlled trial","volume":"303","author":"Saiman","year":"2010","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1378\/chest.12-0628","article-title":"Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa","volume":"142","author":"Ratjen","year":"2012","journal-title":"Chest"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000239440","article-title":"The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro","volume":"42","author":"Ichimiya","year":"1996","journal-title":"Chemotherapy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"ref_17","unstructured":"(2024, September 01). Rayyan. Available online: https:\/\/rayyan.ai\/."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.urolonc.2013.10.003","article-title":"Assessing the quality of studies on the diagnostic accuracy of tumor markers","volume":"32","author":"Goebell","year":"2014","journal-title":"Urol Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1136\/bmjebm-2022-112102","article-title":"Using Risk of Bias 2 to assess results from randomised controlled trials: Guidance from Cochrane","volume":"28","author":"Flemyng","year":"2023","journal-title":"BMJ Evid. Based Med."},{"key":"ref_20","unstructured":"(2024, September 01). RevMan: Systematic Review and Meta-Analysis Tool for Researchers Worldwide | Cochrane RevMan. Available online: https:\/\/revman.cochrane.org\/info."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1164\/rccm.201802-0215OC","article-title":"Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial","volume":"198","author":"Kloster","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_22","first-page":"429","article-title":"Role of Long-Term Intermittent Use of Oral Azithromycin On Pulmonary Exacerbations In Cystic Fibrosis Children","volume":"32","author":"Aziz","year":"2020","journal-title":"J. Ayub Med. Coll. Abbottabad"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1159\/000453451","article-title":"Steady-State Therapy with Azithromycin or Low-Dose Prednisolone in Paediatric Cystic Fibrosis Patients: Inflammatory Markers and Disease Progression","volume":"172","author":"Shmarina","year":"2017","journal-title":"Int. Arch. Allergy Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/S2213-2600(22)00165-5","article-title":"The effect of azithromycin on structural lung disease in infants with cystic fibrosis (COMBAT CF): A phase 3, randomised, double-blind, placebo-controlled clinical trial","volume":"10","author":"Stick","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1513\/AnnalsATS.201811-774OC","article-title":"Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis","volume":"16","author":"Klingel","year":"2019","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/ppul.21601","article-title":"Open-label, follow-on study of azithromycin in pediatric patients with CF uninfected with Pseudomonas aeruginosa","volume":"47","author":"Saiman","year":"2012","journal-title":"Pediatr. Pulmonol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(02)11081-6","article-title":"Long term azithromycin in children with cystic fibrosis: A randomised, placebo-controlled crossover trial","volume":"360","author":"Equi","year":"2002","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1136\/thx.2005.057950","article-title":"Long term effects of azithromycin in patients with cystic fibrosis: A double blind, placebo controlled trial","volume":"61","author":"Clement","year":"2006","journal-title":"Thorax"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/01.mcp.0000142101.53084.f0","article-title":"The use of macrolide antibiotics in patients with cystic fibrosis","volume":"10","author":"Saiman","year":"2004","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10156-007-0555-2","article-title":"Suppression of Pseudomonas aeruginosa quorum-sensing systems by macrolides: A promising strategy or an oriental mystery?","volume":"13","author":"Tateda","year":"2007","journal-title":"J. Infect. Chemother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1164\/rccm.200402-200OC","article-title":"Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection","volume":"170","author":"Tsai","year":"2004","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1164\/rccm.200601-071OC","article-title":"Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome","volume":"174","author":"Verleden","year":"2006","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/j.bbrc.2006.09.132","article-title":"Anti-inflammatory effects of azithromycin in cystic fibrosis airway epithelial cells","volume":"350","author":"Cigana","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/1465-9921-7-134","article-title":"Azithromycin reduces spontaneous and induced inflammation in DeltaF508 cystic fibrosis mice","volume":"7","author":"Legssyer","year":"2006","journal-title":"Respir. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: Mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Venditto, V.J., Haydar, D., Abdel-Latif, A., Gensel, J.C., Anstead, M.I., Pitts, M.G., and Feola, D.J. (2021). Immunomodulatory Effects of Azithromycin Revisited: Potential Applications to COVID-19. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.574425"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Parnham","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"10","DOI":"10.21037\/tgh-23-59","article-title":"The current state of gastrointestinal motility evaluation in cystic fibrosis: A comprehensive literature review","volume":"9","author":"Davis","year":"2024","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_39","first-page":"390","article-title":"Azithromycin Induces Migrating Motor Complexes in Pediatric Patients Undergoing Antroduodenal Motility Studies","volume":"23","author":"Shakir","year":"2018","journal-title":"J. Pediatr. Pharmacol. Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/19490976.2020.1870402","article-title":"Association between antibiotics and gut microbiome dysbiosis in children: Systematic review and meta-analysis","volume":"13","author":"McDonnell","year":"2021","journal-title":"Gut Microbes"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e24427","DOI":"10.1002\/jcla.24427","article-title":"Mechanism of action, resistance, synergism, and clinical implications of azithromycin","volume":"36","author":"Heidary","year":"2022","journal-title":"J. Clin. Lab. Anal."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa043526","article-title":"Azithromycin for the secondary prevention of coronary events","volume":"352","author":"Grayston","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jcf.2016.12.003","article-title":"Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis","volume":"16","author":"Nichols","year":"2017","journal-title":"J. Cyst. Fibros."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1513\/AnnalsATS.201310-352OC","article-title":"Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis","volume":"11","author":"Nick","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1128\/AAC.02067-13","article-title":"Meta-analysis of the adverse effects of long-term azithromycin use in patients with chronic lung diseases","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_48","first-page":"7","article-title":"Disease-modifying drug therapy in cystic fibrosis","volume":"26","author":"Harman","year":"2018","journal-title":"Paediatr. Respir. Rev."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/653\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:08:33Z","timestamp":1760029713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/61\/4\/653"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,2]]},"references-count":48,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["medicina61040653"],"URL":"https:\/\/doi.org\/10.3390\/medicina61040653","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,2]]}}}